

Saturday, 16 October 2021, 13.00-17.15 CEST

Moderators:

M. Rouprêt, Paris (FR)
A. Stenzl, Tübingen (DE)

13.00 – 13.55 Update on imaging of localized prostate cancer and risk stratification

Chairs: M. Rouprêt, Paris (FR)
J. Walz, Marseille (FR)

13.00 – 13.10 How to do early detection in the era of mpMRI?

H. Gronberg, Stockholm (SE)

13.10 – 13.25 PCa suspicion but negative MRI

13.10 – 13.13 Case presentation

V. Kasivisvanathan, London (GB)

13.13 – 13.23 Debate

H. Gronberg, Stockholm (SE)
V. Kasivisvanathan, London (GB)
N. Mottet, Saint-Étienne (FR)

13.23 – 13.25 Conclusion/wrap-up

J. Walz, Marseille (FR)

13.25 – 13.35 PSMA-PET for initial staging: The new standard for everybody?

R. Abrams-Pompe, Hamburg (DE)

13.35 – 13.50 Case negative on conventional imaging but positive for 1 lesion on PSMA: What to offer?

13.35 – 13.38 Case presentation

R. Abrams-Pompe, Hamburg (DE)

13.38 – 13.48 Debate

R. Abrams-Pompe, Hamburg (DE)
S. Joniau, Leuven (BE)
N. Mottet, Saint-Étienne (FR)

13.48 – 13.50 Conclusion /wrap-up

J. Walz, Marseille (FR)

13.50 – 13.55 Biopsy & imaging

N. Mottet, Saint-Étienne (FR)

13.55 – 14.05 Break

14.05 – 15.00 Update on locally advanced and oligometastatic prostate cancer

Chairs: S. Joniau, Leuven (BE)
M. Rouprêt, Paris (FR)

14.05 – 14.15 High-risk PCa features post-radical prostatectomy: The case for adjuvant RT

G. De Meerleer, Leuven (BE)

- 14.15 – 14.30 Clinically node-positive PCa**
14.15 – 14.18 Case presentation
S. Joniau, Leuven (BE)
14.18 – 14.28 Debate
A. Briganti, Milan (IT)
N. James, London (GB)
14.28 – 14.30 Conclusion/wrap-up
S. Joniau, Leuven (BE)
- 14.30 – 14.40 The role of novel imaging in the work-up of biochemical recurrence after local treatment**
J-P. Radtke, Essen (DE)
- 14.40 – 14.55 Oligometastatic recurrence after local treatment**
14.40 – 14.43 Case presentation
P. Blanchard, Villejuif (FR)
14.43 – 14.53 Debate
A. Briganti, Milan (IT)
N. James, London (GB)
14.53 – 14.55 Conclusion/wrap-up
P. Blanchard, Villejuif (FR)
- 14.55 – 15.00 Persistent PSA, adjuvant EBRT (and again salvage EBRT)**
N. Mottet, Saint-Étienne (FR)
- 15.00 – 15.10 Break**
- 15.10 – 16.05 Update on metastatic prostate cancer: mCRPC & mHSPC**
Chairs: A. Merseburger, Lübeck (DE)
J. Bellmunt, Boston (US)
- 15.10 – 15.20 Parp inhibitors: Is everything so clear?**
E. Castro, Madrid (ES)
- 15.20 – 15.35 Why I start with ADT plus NHT and not chemotherapy?**
15.20 – 15.23 Case presentation
L-M. Krabbe, Münster (DE)
15.23 – 15.33 Debate
A. Merseburger, Lübeck (DE)
J. Bellmunt, Boston (US)
15.33 – 15.35 Conclusion/wrap-up
A. Stenzl, Tübingen (DE)
- 15.35 – 15.45 Cross resistance between treatment: Where do we stand?**
J. Bellmunt, Boston (US)
- 15.45 – 16.00 A fit 81 year old man with mCRPC: How to manage?**
15.45 – 15.48 Case presentation
A. Alberts, Rotterdam (NL)
15.48 – 15.58 Debate
A. Merseburger, Lübeck (DE)
J. Bellmunt, Boston (US)
J. van Moorselaar, Amsterdam (NL)
15.58 – 16.00 Conclusion/wrap-up
A. Stenzl, Tübingen (DE)

- 16.00 – 16.05 First line M1 treatment, sequencing in mCRPC**
N. Mottet, Saint-Étienne (FR)
- 16.05 – 16.15 Break**
- 16.15 – 17.10 Update on the role of genetic in clinical management of prostate cancer**
Chairs: A. Stenzl, Tübingen (DE)
A. Briganti, Milan (IT)
- 16.15 – 16.25 Somatic mutation assessment: When and for whom?**
P. Cornford, Liverpool (GB)
- 16.25 – 16.40 Case with high risk/locally advanced prostate cancer**
16.25 – 16.28 Case presentation
G. Giannarini, Udine (IT)
16.28 – 16.38 Debate
H. Van der Poel, Amsterdam (NL)
A. Heidenreich, Cologne (DE)
16.38 – 16.40 Conclusion/wrap-up
A. Stenzl, Tübingen (DE)
- 16.40 – 16.50 Germline mutations in prostate cancer: What to search and in whom?**
J. Mateo, Barcelona (ES)
- 16.50 – 17.05 De novo metastatic prostate cancer**
16.50 – 16.53 Case presentation
G. Gandaglia, Udine (IT)
16.53 – 17.03 Debate
T. Steuber, Hamburg (DE)
U. Vogl, Bellinzona (CH)
17.03 – 17.05 Conclusion/wrap-up
A. Briganti, Milan (IT)
- 17.05 – 17.10 Upfront use: Use in the CRPC situations**
N. Mottet, Saint-Étienne (FR)
- 17.10 – 17.15 Closure**
M. Rouprêt, Paris (FR)
A. Stenzl, Tübingen (DE)